Viewing nowLyrica Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Baskan Bio Pharmaceutical Co., Ltd.

MFDS item code 201702148 · Approved 2017.04.27 · Insurance code 656204760
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults and serves as an adjunct in patients with epilepsy experiencing partial seizures. It also helps alleviate the symptoms of fibromyalgia and is effective in improving symptoms of various neurological disorders.
The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be given at an initial dose of 150 mg daily. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg daily after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Daily dosage according to renal function: Creatinine clearance ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance ≥30 -<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance ≥15 -<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: A supplemental dose is an additional dose administered once. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so mood changes or symptoms of depression should be carefully monitored during treatment. People with allergies to the ingredients in this medication should not take it, and patients with genetic issues related to lactose should also avoid it. Diabetic patients should be cautious as weight gain may necessitate dose adjustments of blood sugar control medications. If serious allergic reactions such as angioedema occur, discontinue use immediately. Elderly patients should be cautious when taking this medication as dizziness, drowsiness, or confusion may occur, which may increase the risk of falls. Transient visual disturbances or changes in vision may occur, and if symptoms persist, consulting a physician is advised. When discontinuing this medication, withdrawal symptoms such as insomnia, headache, and anxiety may occur, so dosage should be gradually reduced under medical supervision. There is a risk of drug abuse, so patients with a history of substance abuse or mental disorders must consult their healthcare provider before use. Patients with impaired kidney function may require dose adjustments; kidney status should be monitored. Patients with heart diseases may experience symptoms of congestive heart failure while taking this medication, so caution is necessary. When this medication is taken with opioid analgesics, CNS depressant effects may increase, posing a risk of respiratory depression. Activities requiring alertness, such as driving or operating machinery, should be avoided until dizziness or drowsiness subsides. During early pregnancy, this medication may pose risks to the fetus, so women who are pregnant or planning to become pregnant should discuss use with their doctor and use effective contraception. Breastfeeding women are advised to discontinue breastfeeding during treatment with this medication due to potential transmission in breast milk affecting the infant. Special caution is needed when giving this medication to children or the elderly, and children should be kept out of reach. In case of overdose, symptoms such as confusion, drowsiness, or depression may appear, and appropriate treatment such as dialysis may be necessary. Serious rashes or allergic reactions on the skin should result in immediate discontinuation of the medication and consultation with a healthcare provider.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, therefore, it should be stored in a tightly closed container. Additionally, it is important to store it in a cool place between 15 and 30 degrees Celsius to maintain efficacy.
A white powder in a hard capsule with a white upper and lower part, which may appear white or light yellow.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Baskan Bio Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.